Staren v. Clarivate Analytics (US) LLC

District Court, D. Arizona·Decided January 7, 2025·No. 2:23-cv-02091·Unknown

Opinion

WO

Anthony Staren, an individual, No. CV-23-02091-PHX-DWL

Plaintiff, ORDER

v.

Clarivate Analytics (US), LLC, a Delaware limited liability company, Defendant. Anthony Staren (“Plaintiff”) contends that his former employer, Clarivate Analytics (“Defendant”), failed to pay him over $500,000 in sales commissions to which he was entitled under Defendant’s “2022 Sales Incentive Plan” (hereinafter, the “Incentive Plan”). In this action, Plaintiff asserts claims under the Arizona Wage Act (“AWA”) and the covenant of good faith and fair dealing and also seeks declaratory relief concerning the validity of certain provisions in the Incentive Plan. (Doc. 14.) Now pending before the Court are Plaintiff’s motion for judgment on the pleadings as to his claim for declaratory relief and Defendant’s cross-motion for judgment on the pleadings as to all of Plaintiff’s claims. (Docs. 26, 31.) For the reasons that follow, Plaintiff’s motion is denied and Defendant’s motion is granted in part and denied in part. BACKGROUND The following facts are derived from the parties’ operative pleadings, the complaint (Doc. 14) and the answer (Doc. 18). For purposes of Plaintiff’s motion, the denials and affirmative allegations contained in Defendant’s answer are presumed true. For purposes of Defendant’s cross-motion, the allegations contained in the complaint are presumed true. I. Factual Allegations Plaintiff was employed by Defendant from December 2021 through June 2023. (Doc. 1447). During his employment, Plaintiff “participated in Clarivate’s 2022 Sales Incentive Plan.” (Ud. 48). “The Incentive Plan provides that commissions are deemed fully earned and payable to a participant upon closure or invoicing of eligible sales during 7\| the employee’s term of employment.” (/d. 9.) Plaintiff alleges that “[iJn 2022 he began working on a sale with Diaceutics, Inc,” and “[t]hroughout 2022, [he] was personally involved in all aspects of the Diaceutics sales and regularly exchanged emails and phone calls with various members of Diaceutics, as well as other Clarivate employees to ensure that the sale could and would go through.” (/d. 12] 11-12.) Plaintiff also alleges that “[a]t the end of 2022, [he] successfully negotiated and 13) closed the Diaceutics deal, which totaled $3.777 million.” (/d. 413.) Defendant denies these allegations regarding Plaintiffs involvement in closing the Diaceutics sale. (Doc. 18 11-13.) On December 30, 2022, after Plaintiff allegedly closed the Diaceutics deal, Defendant published an internal report entitled “Daily Close Performance and Deals” that contained a section entitled “Top Business Deals From the Previous Business Day.” (Doc. 149 14-15.) It contained the following entry: $ Top businessideals fron the previous business day($M) 92 eg ee i epee onesie □□□□ 9k Piaseuuesing □ Ony'Staren ew esiness □□

Ud. 416). According to Plaintiff, this entry states that he “closed the Diaceutics . .. sale □□ for $3.777 million.” (d.) Defendant admits the existence of this entry but alleges in its answer that the entry was “auto-generated by a software platform based upon unverified 97 self-report data entered by sales and other non-management employees prior to review and approval by Company management. Defendant denies any implication that the auto-

_2-

generated information reflects evidence that Plaintiff was the ‘Rep’ responsible for the Diaceutics Inc. sale.” (Doc. 18 ¶ 16.) On January 19, 2023, Plaintiff was invited to Defendant’s April 2023 “Winner’s Circle” trip, which was a five-night company-paid trip to Hawaii. (Doc. 14 ¶ 17; Doc. 18 ¶ 17.) Plaintiff additionally alleges that this trip was given as a “reward . . . for those commissioned employees, like [him], whose revenue for sales beyond the necessary target amount qualified them for the trip” and that he “would not have qualified for the trip without the Diaceutics sale.” (Doc. 14 ¶¶ 17-18.) Defendant denies these additional allegations. (Doc. 18 ¶¶ 17-18.) On January 31, 2023, Plaintiff had a phone call with Darren Tickle, a Clarivate executive, regarding the Diaceutics sale. (Doc. 14 ¶ 20). Following this call, Plaintiff emailed Tickle to express his belief that he was entitled to a $528,944.95 commission arising from the Diaceutics sale according to the terms of the Incentive Plan. (Id. ¶ 21.) In response, Tickle stated that “the Diaceutics sale constituted a ‘Real World Data partner deal’ that did not qualify as part of Mr. Staren’s 2022 territory and that ‘given the misalignment of the deal to [his] Incentive Plan and the exceptional nature of the deal, any compensation for this deal is within the sole discretion of Clarivate Management.’” (Id. ¶ 22.) Plaintiff alleges, and Defendant admits, that the phrase “Real World” does not appear in the Incentive Plan attached to the complaint. (Id. ¶ 23; Doc. 18 ¶ 23.) Plaintiff alleges that Defendant’s regular practice is to quickly identify a deal as a “Real World Data partner deal” and interject before the employee closes the deal, but in this case, management “knew of and supported his efforts in the Diaceutics deal” and never questioned whether it would qualify as an eligible sale. (Doc. 14 ¶¶ 24-26.) Defendant denies these allegations. (Doc. 18 ¶¶ 24-26.) Plaintiff alleges that, in refusing to pay him the commission, Defendant “relied on various provisions in the Incentive . . . Plan that purport to give [Defendant] unilateral and complete discretionary authority to reduce, even retroactively without warning, any sale that [Defendant] chose to reduce.” (Doc. 14 ¶ 27.) Defendant “denies that said allegations are a complete and accurate summary of the contents and/or relevant provisions of the [Incentive Plan] or the parties’ relevant communications on this topic, and Defendant denies that Plaintiff is entitled to any additional unpaid compensation under the Plan.” (Doc. 18 ¶ 27.) The complained-of provisions are as follows:

Achievement above Target. The core Clarivate Sales Incentive Plan is an uncapped Plan that aims to provide exceptional rewards for exceptional performance. The plan components may generate unlimited commission earnings in-line with target achievement %. However, there may be rare scenarios where achievement is misaligned to the target that was set for a territory. In such cases, Clarivate Management reserves the right to review whether the target, territory size, pay-out rate and bonus objectives were appropriately set, and, where applicable, adjust the levels and/or associated commission earnings.

Free access — add to your briefcase to read the full text and ask questions with AI

Staren v. Clarivate Analytics (US) LLC, (D. Ariz. 2025).

Staren v. Clarivate Analytics (US) LLC (Staren v. Clarivate Analytics (US) LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wilkinson v. Leland
27 U.S. 627 (Supreme Court, 1829)
Calderon v. Ashmus
523 U.S. 740 (Supreme Court, 1998)
Bartlett v. Strickland
556 U.S. 1 (Supreme Court, 2009)
In Re GRAND JURY
566 F.3d 12 (First Circuit, 2009)
Cafasso v. General Dynamics C4 Systems, Inc.
637 F.3d 1047 (Ninth Circuit, 2011)
Horizon Corp. v. Westcor, Inc.
688 P.2d 1021 (Court of Appeals of Arizona, 1984)
Maxwell v. Fidelity Financial Services, Inc.
907 P.2d 51 (Arizona Supreme Court, 1995)
Shattuck v. Precision-Toyota, Inc.
566 P.2d 1332 (Arizona Supreme Court, 1977)
Aetna Casualty & Surety Co. v. PPG Industries, Inc.
554 F. Supp. 290 (D. Arizona, 1983)
McCollum v. XCare. Net, Inc.
212 F. Supp. 2d 1142 (N.D. California, 2002)
City of Fairbanks v. Rice
20 P.3d 1097 (Alaska Supreme Court, 2000)
Estate of Nelson v. Rice
12 P.3d 238 (Court of Appeals of Arizona, 2000)
Meghan Mollett v. Netflix, Inc.
795 F.3d 1062 (Ninth Circuit, 2015)
Clark v. Renaissance West, LLC
307 P.3d 77 (Court of Appeals of Arizona, 2013)
Fajardo v. County of Los Angeles
179 F.3d 698 (Ninth Circuit, 1999)